{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:27:11Z","timestamp":1762018031842,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.nmd.2017.06.001","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T03:32:45Z","timestamp":1496460765000},"page":"914-917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Double-seropositive myasthenia gravis with acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies associated with invasive thymoma"],"prefix":"10.1016","volume":"27","author":[{"given":"Hidehiro","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunya","family":"Nakane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Asahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Tomimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2017.06.001_bib0010","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.06.001_bib0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis \u2013 autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nmd.2017.06.001_bib0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2017.06.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135378","article-title":"Flow cytofluorimetric analysis of anti-LRP4 (LDL receptor-related protein 4) autoantibodies in Italian patients with myasthenia gravis","volume":"10","author":"Marino","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2017.06.001_bib0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5692\/clinicalneurol.53.372","article-title":"A case of thymoma-associated myasthenia gravis with anti-MuSK antibodies","volume":"53","author":"Ito","year":"2013","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.nmd.2017.06.001_bib0035","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/mus.24166","article-title":"Double seropositive myasthenia gravis with acetylcholine receptor-related protein 4 antibodies","volume":"49","author":"Tsivgoulis","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2017.06.001_bib0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nmd.2017.06.001_bib0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","article-title":"The search for new antigenic targets in myasthenia gravis","volume":"1275","author":"Cossins","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2017.06.001_bib0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Science Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.06.001_bib0055","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/ene.13081","article-title":"Electrophysiological findings in patients with low density lipoprotein receptor related protein 4 positive myasthenia gravis","volume":"23","author":"Nikolic","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2017.06.001_bib0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jneuroim.2013.12.012","article-title":"ACh-R-myasthenia gravis switching to double-seropositive several years after the onset","volume":"267","author":"Zouvelou","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2017.06.001_bib0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.nmd.2017.06.001_bib0075","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2017.06.001_bib0060","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","article-title":"Prognosis of ocular myasthenia gravis: retrospective multicenter analysis","volume":"122","author":"Nagia","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.nmd.2017.06.001_bib0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2015.03.018","article-title":"Prognostic factors for exacerbations and emergency treatments in myasthenia gravis","volume":"282","author":"de Meel","year":"2015","journal-title":"J Neuroimmunol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616307854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616307854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:05:34Z","timestamp":1760774734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896616307854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0960896616307854"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2017.06.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double-seropositive myasthenia gravis with acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies associated with invasive thymoma","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2017.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}